TransCode Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
TransCode Therapeutics has a total shareholder equity of $1.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $4.8M and $3.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$3.35m |
| Equity | US$1.32m |
| Total liabilities | US$3.50m |
| Total assets | US$4.82m |
Recent financial health updates
Recent updates
TransCode Therapeutics reports Q2 results
Aug 15TransCode files U.S. patent application for radiotherapy based cancer treatment
Jul 11We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely
Apr 01
Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation
Dec 15Financial Position Analysis
Short Term Liabilities: RNAZ's short term assets ($4.4M) exceed its short term liabilities ($3.5M).
Long Term Liabilities: RNAZ has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: RNAZ is debt free.
Reducing Debt: RNAZ currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RNAZ has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: RNAZ is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.